Treating Mental Illnesses and Psychiatric Disorders
The use of Psychedelic drugs for treating Mental Illnesses and Psychiatric Disorders is getting huge attention lately. “Plant-based medicine” and “PsyTech” have become popular terms for Psychedelic health care last year and this field is getting more and more interesting and popular all over the world.
Recent Research and science show that with the help of psychedelics, many patients succeeded to overcome their mental health issues.
In November 2021, Texas government agencies recently gave their approval to carry out research on psychedelics as a possible treatment for post-traumatic stress syndrome (PTSD). More US states have started to discuss the potential of psychedelic treatments lately and many US lawmakers from Michigan, New Hampshire, Missouri, Kansas, and Virginia are offering to decentralize Psylocibin and other psychoactive drugs and even psychedelic possessions.
Here’s a short list of helpful terms in psychedelic medicine:
- Psilocybin – This is the active-Ingredient found in mushrooms and has a hallucinogenic effect.
- Ketamine – an opiate that leads to a state of trance.
- Ibogaine – a natural psychoactive drug that’s found in some plants.
- MDMA – a psychoactive drug also called the ‘love drug’ and used recreationally by people from nearly all backgrounds.
- DMT is a naturally occurring chemical in our brain and in certain animals and plants. It’s used primarily as a recreational drug and its effects are usually short-term, lasting just a few minutes.
- LSD is a highly potent hallucinogen and can change people’s perception of reality, sometimes even permanently.
Media outlets have been talking about the growth potential of PsyTech and whether this may be the “next hot sector” of stock trading. Nowadays there’s a psychedelic exchange-traded fund (ETF) — known as the Defiance Next Gen Altered Experience ETF (NYSE: PSY). these might be just a few signs of considerable potential in the psychedelic space as it attracts attention from mainstream players.
A psychedelic medicine company will launch a phase two clinical trial on its sublingual formulation of psilocybin, the psychedelic compound found in “magic mushrooms”, for patients with Major Depressive Disorder later this year https://t.co/wechJsdIY6 pic.twitter.com/QT132Tk1DC
— Forbes (@Forbes) June 2, 2021
The science of Psychedelic treatments is in its developmental stages. Most firms operating in this sector are considered early-stage initiatives that usually trade on the OTC markets, so whoever is interested in getting into trading psychedelic stocks, may not have the option to trade most of them via Robinhood or some other popular digital investment platform.
However, as we continue to see more scientific innovations and related developments, it’s possible we may also see established businesses getting on board. Before choosing any stock, it’s important to familiarize oneself with this nascent space and the current treatments the company is working on. If you take the time to do your research, then you may be ready to take advantage of future developments.
When “news” or a solid narrative hits any of these stocks, it might lead to sympathy plays in the wider sector. Moreover, the demand for psychedelic treatments continues to rise and research specialists come across new developments, we all might see even more firms joining this nascent sector. This is somewhat like what we’ve been witnessing in other emerging industries as well.